Avastin fails stomach-cancer trial

Roche got a big disappointment today: The cancer drug Avastin failed a clinical trial in stomach cancer, one of the new indications the drugmaker had been aiming for. The company had predicted sales for stomach-cancer patients could have reached as high as 1 billion Swiss francs, or $933 million.

Here's the scoop: Avastin failed to meet its primary target of extending overall survival in patients using it in combination with chemotherapy, compared with patients on a combo of placebo and chemotherapy, Roche says. "We are disappointed with these results because treatment options for stomach cancer are limited," CMO Hal Barron says in a statement.

Roche says it didn't find any new safety problems in the trial, and that it'll continue working on other new indications for Avastin. Next up: Data on Avastin use in ovarian cancer, expected sometime in the first half of this year.

- check out Roche's release
- read the Reuters story

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.